AbbVie Deutschland GmbH & Co. KG

• Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting
  2024-514465-18-00 Phase I/II 7 countries BUDIGALIMAB; CARBOPLATIN; CISPLATIN; PEMBROLIZUMAB; PEMETREXED; TELISOTUZUMAB AD…
• Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chem… Recruiting
  2023-505773-32-00 Phase II/III 4 countries BUDIGALIMAB; CARBOPLATIN; CISPLATIN; LIVMONIPLIMAB; PEMBROLIZUMAB; PEMETREXED
• This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting
  2023-504713-76-00 Phase III 12 countries UPADACITINIB
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 Phase II 23 countries ABBV-8736; HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST ALFA4BETA7 INTEGRIN;…
• Study evaluating the Safety and Efficacy of Etentamig (ABBV-383) in Subjects with Light Chain Amyloidosis Recruiting
  2023-503429-20-00 3 countries
• Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budiga… Recruiting
  2023-504600-28-00 Phase II/III 3 countries BUDIGALIMAB; DURVALUMAB; LIVMONIPLIMAB
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 Phase III 18 countries UPADACITINIB
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoria… Recruiting
  2022-500408-22-00 Phase III 3 countries RISANKIZUMAB
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Recruiting
  2023-505347-38-00 Phase I/II 7 countries CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; EPCORITAMAB; GOLCADOMIDE; IBRUTINIB…
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants Wi… Recruiting
  2023-504599-10-00 Phase II 6 countries OBINUTUZUMAB; VENETOCLAX
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended
  2024-518998-33-00 Phase III 20 countries RISANKIZUMAB; VEDOLIZUMAB
• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended
  2023-506842-22-00 Phase I (FiH) 7 countries BRIMONIDINE TARTRATE; IMGN151; PREDNISOLONE ACETATE
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended
  2024-512946-41-00 Phase III 7 countries ATOGEPANT
• Crohn's Disease: Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn’s Disease Ended
  2024-516023-13-00 Phase III 4 countries RISANKIZUMAB
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended
  2024-510730-40-00 Phase III 22 countries LUTIKIZUMAB
• Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 W… Ended
  2023-505110-14-00 Phase II 3 countries TELISOTUZUMAB ADIZUTECAN
• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination with Intravenously… Ended
  2024-512147-23-00 Phase II/III 3 countries ACALABRUTINIB; OBINUTUZUMAB; VENETOCLAX
• A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec… Ended
  2023-505617-24-00 Phase II 4 countries BRIMONIDINE TARTRATE; MIRVETUXIMAB SORAVTANSINE; PREDNISOLONE ACETATE
• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu… Ended
  2024-510965-41-00 Phase III 11 countries EPCORITAMAB; GEMCITABINE; LENALIDOMIDE; OXALIPLATIN; RITUXIMAB
• Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell… Ended
  2023-503594-38-00 Phase I 4 countries
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended
  2023-505061-82-01 Phase III 13 countries UPADACITINIB
• A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended
  2023-506668-15-00 Phase III 13 countries ETENTAMIG
• A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participan… Ended
  2023-503666-23-00 Phase III 5 countries AFLIBERCEPT; RANIBIZUMAB; SURABGENE LOMPARVOVEC
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended
  2023-506906-38-00 Phase III 17 countries BENDAMUSTINE HYDROCHLORIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; EPCORIT…

Showing 49–72 of 138 trials